Cara Therapeutics - CARA Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CARA shares.
View CARA analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month target prices for Cara Therapeutics' stock. Their CARA share price forecasts range from $20.00 to $30.00. On average, they anticipate the company's share price to reach $26.80 in the next twelve months. This suggests a possible upside of 137.6% from the stock's current price.
View analysts price targets for CARA or view top-rated stocks among Wall Street analysts.

Cara Therapeutics' stock was trading at $12.18 at the start of the year. Since then, CARA shares have decreased by 7.4% and is now trading at $11.28.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our CARA earnings forecast.

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.34. The biopharmaceutical company earned $20.27 million during the quarter, compared to analyst estimates of $15.74 million. Cara Therapeutics had a negative net margin of 135.72% and a negative trailing twelve-month return on equity of 31.47%. During the same period in the prior year, the firm posted ($0.35) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (4.93%), State Street Corp (3.64%), Chescapmanager LLC (2.16%), Millennium Management LLC (1.45%), Pinnacle Associates Ltd. (1.39%) and Northern Trust Corp (1.24%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends.

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CARA stock can currently be purchased for approximately $11.28.

Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $606.03 million and generates $23.03 million in revenue each year. The biopharmaceutical company earns $-88,440,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.